Wobser M, Rosenwald A, Eisele F, Maurus K, et al. Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma. Leuk Lymphoma 2026 May 22:1-4. doi: 10.1080/10428194.2026.2672106.
PMID: 42169664